# A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

> **NCT01708161** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- PIK3CA Mutated Advanced Solid Tumors
- PIK3CA Amplified Advanced Solid Tumors

## Interventions

- **DRUG:** BYL719
- **DRUG:** AMG 479

## Key facts

- **NCT ID:** NCT01708161
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-27
- **Primary completion:** 2014-12-26
- **Final completion:** 2017-06-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01708161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01708161, "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01708161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*